A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.

Key facts

Study ID

NCT07232589

Run by

Merck Sharp & Dohme LLC

People needed

26

Starts

2025-12-08

Expected to finish

2026-06-17

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be in good health
• BMI between 18.5 and 32 kg/m2, inclusive

You may not qualify if…

• History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological (history of a bleeding disorder, abnormal bleeding or a hereditary or acquired coagulation or platelet disorder), hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke, intercranial hemorrhage, and chronic seizures) abnormalities or diseases
• History of cancer (malignancy)

Where it is running

• Fortea CRU Madison ( Site 0001) — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.